Effect of antidiabetic therapy on TNF-α, IL-18, IL-23 and IL-35 levels in T2DM patients with coincidental Helicobacter pylori infection

References

• Vieira R, Souto SB, Sánchez-López E, et al. Sugar-Lowering drugs for Type 2 diabetes mellitus and metabolic syndrome-review of classical and new compounds: part-I. Pharmaceuticals (Basel). 2019;12(4):152. doi:10.3390/ph12040152.
   Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International diabetes federation diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843.
   PubMed Web of Science ®Google Scholar
• Francisco CO, Catai AM, Moura-Tonello SC, et al. Cytokine profile and lymphocyte subsets in type 2 diabetes. Braz J Med Biol Res. 2016;49(4):e5062. doi:10.1590/1414-431X20155062.
   Web of Science ®Google Scholar
• Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance. J Clin Endocrinol & Metab. 2008;93(8):3165–3172.
   PubMed Web of Science ®Google Scholar
• Hivert MF, Sun Q, Shrader P, et al. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia. 2009;52(10):2101–2108.
   PubMed Web of Science ®Google Scholar
• Kalninova J, Jakus V, Glejtkova M, et al. Impact of glycemic control on advanced glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus. Bratisl Lek Listy. 2014;115(8):457–468. doi:10.4149/bll_2014_089.
   Web of Science ®Google Scholar
• Hasnain SZ, Borg DJ, Harcourt BE, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014;20(12):1417–1426.
   PubMed Web of Science ®Google Scholar
• Yan A, You H, Zhang X. Levels of interleukin 27 and interleukin 35 in the serum and Vitreous of patients with proliferative diabetic retinopathy. Ocul Immunol Inflamm. 2018;26(2):273–279.
   PubMed Web of Science ®Google Scholar
• World Gastroenterology Organisation. World gastroenterology organisation global guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol. 2011;45(5):383–388.
   PubMed Web of Science ®Google Scholar
• Kayar Y, Pamukçu Ö, Eroğlu H, et al. Relationship between Helicobacter pylori infections in diabetic patients and inflammations, metabolic syndrome, and complications. J Int Chronic Dis. 2015;2015:290128. doi:10.1155/2015/290128.
   PubMedGoogle Scholar
• Rafat MN, Azeem HA, Antably A, et al. Prevalence of Helicobacter pylori infection in patients with type 2 diabetes mellitus. AAMJ. 2015;13:4.
   Google Scholar
• Hosseininasab Nodoushan SA, Nabavi A. The Interaction of Helicobacter pylori infection and Type 2 diabetes mellitus. Adv Biomed Res. 2019;8:15. doi:10.4103/abr.abr_37_18.
   Google Scholar
• Bagheri N, Taghikhani A, Rahimian G, et al. Association between virulence factors of helicobacter pylori and gastric mucosal interleukin-18 mRNA expression in dyspeptic patients. Microb Pathog. 2013;65:7–13.
   PubMed Web of Science ®Google Scholar
• Mentis A, Lehours P, Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. 2015;20(1):1–7.
   Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J. 2010;103:190–196.
   PubMed Web of Science ®Google Scholar
• Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harb Perspect Med. 2012;2(3):a007724. doi:10.1101/cshperspect.a007724.
   PubMed Web of Science ®Google Scholar
• Manco M, Putignani L, Bottazzo GF, et al. Lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31(6):817–844.
   PubMed Web of Science ®Google Scholar
• Hsieh MC, Wang SW, Hsieh YT, et al. Helicobacter pylori infection associated with high HbA1c and type 2 diabetes. Eur J Clin Inves. 2013;43(9):949–956.
   PubMed Web of Science ®Google Scholar
• Francois F, Roper J, Joseph N, et al. The effect of H. pylori eradication on meal associated changes in plasma ghrelin and leptin. BMC Gastroent. 2011;11:37.
   Web of Science ®Google Scholar
• Kasai C, Sugimoto K, Moritani I, et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. BMC Gastroenterol. 2016;16(1):119.
   PubMedGoogle Scholar
• Taghdir M, Djazayeri A, Djalali M, et al. Relationships of serum leptin concentration with insulin, glucose, HbA1c levels and insulin resistance in overweight post-menopausal diabetic women. ARYA Atheroscler J. 2010;5(4):175–180.
   Google Scholar
• Sarr O, Strohm RJ, MacDonald TL, et al. Subcutaneous and visceral adipose tissue secretions from extremely obese men and women both acutely suppress muscle insulin signaling. Int J Mol Sci. 2017;18(5):pii: E959.
   Web of Science ®Google Scholar
• Cummings BP, Bettaieb A, Graham JL, et al. Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats. Proc Natl Acad Sci U S A. 2011;108(35):14670–14675.
   Web of Science ®Google Scholar
• Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570–578.
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and Pathogenesis of Type 2 diabetes mellitus. J Cell Biochem. 2018;119:105–110.
   PubMed Web of Science ®Google Scholar
• Russo F, Jirillo E, Clemente C, et al. Circulating cytokines and gastrin levels in a symptomatic subject infected by Helicobacter pylori. Immunopharmacol Immunotoxicol. 2001;23(1):13–24.
   PubMed Web of Science ®Google Scholar
• Tang CL, Hao B, Zhang GX, et al. Helicobacter pylori tumor necrosis factor-α inducing protein promotes cytokine expression via nuclear factor-κB. World J Gastroenterol. 2013;19(3):399–403.
   Web of Science ®Google Scholar
• Agarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605–1621.
   Web of Science ®Google Scholar
• Wawrocki S, Druszczynska M, Kowalewicz-Kulbat M, et al. Interleukin 18 (IL-18) as a target for immune intervention. Acta Biochim Pol. 2016;63(1):59–63.
   Web of Science ®Google Scholar
• Ballak DB, Stienstra R, Tack CJ, et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75:280–290.
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Giugliano F, et al. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 2003;26:1647. doi:10.2337/diacare.26.5.1647.
   PubMed Web of Science ®Google Scholar
• Sedda S, Bevivino G, Monteleone G. Targeting IL-23 in Crohn's disease. Expert Rev Clin Immunol. 2018;14(11):907–913.
   PubMed Web of Science ®Google Scholar
• Fatima N, Faisal SM, Zubair S, et al. Emerging role of interleukins IL-23/IL-17 axis and biochemical markers in the pathogenesis of Type 2 diabetes: association with age and gender in human subjects. Int J Biol Macromol. 2017;07:155.
   Google Scholar
• Horvath DJ Jr, Washington MK, Cope VA, et al. IL-23 Contributes to control of chronic Helicobacter pylori infection and the development of T Helper responses in a Mouse Model. Front Immunol. 2012;3:56.
   Web of Science ®Google Scholar
• Arachchi PS, Fernando N, Weerasekera MM, et al. Proinflammatory cytokine IL-17 shows a significant association with Helicobacter pylori infection and Disease Severity. Gastroenterol Res Pract. 2017;2017:6265150. doi:10.1155/2017/6265150.
   Web of Science ®Google Scholar
• Caruso R, Fina D, Paoluzi OA, et al. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol. 2008;38(2):470–478.
   Web of Science ®Google Scholar
• Franco MM, Moraes MM, Daurte PM, et al. Glycemic control and the production of cytokines in diabetic patients with chronic periodontal disease. RGO Rev Gaúch Odontol. 2015;63(4):432–438.
   Google Scholar
• Huang A, Cheng L, He M, et al. Interleukin-35 on B cell and T cell induction and regulation. J Inflamm. 2017;14:16.
   Google Scholar
• Hu D. Role of anti-inflammatory cytokines IL-35 and IL-37 in asthma. Inflamm. 2017;40:697–707.
   Google Scholar
• Bello RO, Chin VK, Abd Rachman IMF, et al. The role, involvement and function(s) of interleukin-35 and interleukin-37 in Disease Pathogenesis. Int J Mol Sci. 2018;19(4):1149.
   Web of Science ®Google Scholar
• Singh K, Kadesjö E, Lindroos J, et al. Interleukin-35 administration counteracts established murine type 1 diabetes–possible involvement of regulatory T cells. Sci Rep. 2015;5:12633. doi:10.1038/srep12633.
   Web of Science ®Google Scholar
• Bassagh A, Abasi MH, Larussa T, et al. Diminished circulating concentration of interleukin-35 in Helicobacter pylori-infected patients with peptic ulcer: Its association with FOXP3 gene polymorphism, bacterial virulence factor CagA, and gender of patients. Helicobacter. 2018;23:e12501. doi:10.1111/hel.12501.
   Web of Science ®Google Scholar
• Manzoor F, Johnson MC, Li C, et al. β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice. Eur J Immunol. 2017;47(1):144–154.
   PubMed Web of Science ®Google Scholar